{"id":"bms-663068","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL3301594","moleculeType":"Small molecule","molecularWeight":"583.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMS-663068 is a small-molecule fostemsavir prodrug that inhibits HIV attachment to CD4+ T cells by targeting the gp120 envelope protein. It represents a novel class of antiretroviral agents that work at the earliest stage of HIV infection, before the virus can fuse with and enter the host cell. This mechanism is distinct from reverse transcriptase inhibitors, protease inhibitors, and integrase inhibitors.","oneSentence":"BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:34.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-experienced HIV-1 infection in combination with other antiretroviral agents"}]},"trialDetails":[{"nctId":"NCT02362503","phase":"PHASE3","title":"Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2015-02-23","conditions":"HIV Infections","enrollment":371},{"nctId":"NCT01009814","phase":"PHASE2","title":"Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2009-11-23","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT01384734","phase":"PHASE2","title":"HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2011-07-26","conditions":"Infection, Human Immunodeficiency Virus","enrollment":254},{"nctId":"NCT02674581","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-02-26","conditions":"HIV Infections","enrollment":30},{"nctId":"NCT02234882","phase":"PHASE1","title":"Study on Pharmacokinetics","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-09-05","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT02277600","phase":"PHASE1","title":"A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-11-05","conditions":"Infection, Human Immunodeficiency Virus","enrollment":32},{"nctId":"NCT02480894","phase":"PHASE1","title":"A Open-label, Drug-Drug Interaction With Maraviroc (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":112},{"nctId":"NCT02138084","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Rifabutin","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-05-14","conditions":"Infection, Human Immunodeficiency Virus","enrollment":102},{"nctId":"NCT02467335","phase":"PHASE1","title":"Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-29","conditions":"Infection, Human Immunodeficiency Virus","enrollment":52},{"nctId":"NCT02666053","phase":"PHASE1","title":"A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-01-27","conditions":"Infection, Human Immunodeficiency Virus","enrollment":72},{"nctId":"NCT02508064","phase":"PHASE1","title":"Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-08-03","conditions":"Infection, Human Immunodeficiency Virus","enrollment":27},{"nctId":"NCT02666001","phase":"PHASE1","title":"A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-01-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":32},{"nctId":"NCT02063360","phase":"PHASE1","title":"DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02-01","conditions":"Infection, Human Immunodeficiency Virus","enrollment":42},{"nctId":"NCT02480881","phase":"PHASE1","title":"A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":26},{"nctId":"NCT02164045","phase":"PHASE1","title":"Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-06-24","conditions":"Infection, Human Immunodeficiency Virus","enrollment":38},{"nctId":"NCT02805556","phase":"PHASE1","title":"Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-03-15","conditions":"Infection, Human Immunodeficiency Virus","enrollment":36},{"nctId":"NCT02859259","phase":"PHASE1","title":"A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2016-08-12","conditions":"Infection, Human Immunodeficiency Virus","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BMS-663068","genericName":"BMS-663068","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-663068 is an HIV attachment inhibitor that blocks the interaction between HIV and the CD4 receptor on host cells, preventing viral entry. Used for Treatment-experienced HIV-1 infection in combination with other antiretroviral agents.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":14,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}